[Pharmacological effects of a new antihypertensive agent with imidazoline structure].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to W Kobinger.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Intravenous injection of 30 micrograms/kg of B-HT 920 (6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo-[4,5-d]-azepine dihydrochloride) into cats lead initially to an increase in blood pressure and then to a long-lasting decrease in blood pressure and heart rate. The central site of the hypotensive and bradycardiac action was demonstrated by the significantly greater effect after intracisternal (i.ci.) than after intravenous injection of B-HT 920, 3 micrograms/kg. The drug decreased the rate of spontaneous discharges in preganglionic splanchnic nerve fibers of normal and noradrenaline-depleted cats (3 micrograms/kg, i.ci.). Vagally mediated reflex bradycardia elicited by angiotensin injection in beta-adrenoceptor-blocked dogs was facilitated by intracisternal injection of 10 micrograms/kg B-HT 920. Both sympathoinhibition and vagal reflex facilitation were antagonized by the alpha-adrenoceptor-blocking agent piperoxan (50 micrograms/kg, i.ci). Therefore, B-HT 920 can be classified as an agent of the clonidine type, despite its different chemical structure. Quantitative differences between B-HT 920 and clonidine are discussed with respect to the greater alpha 2/alpha 1 adrenoceptor activity ratio of the former drug, as reported previously.
We studied two new agents, alinidine (St 567, 2-[N-allyl-N-(2,6-dichlorophenyl)-amino]-2-imidazoline) and AQ-A 39 (5,6-dimethoxy-2-[3[[alpha-(3,4-dimethoxy)-phenylethyl] methylamino]propyl]phthalimidine), in isolated guinea pig atria with respect to their specificity to decrease heart rate but not contractility during beta-adrenoceptor stimulation. Spontaneous electrical activity in sinoatrial node preparations was increased by perfusion with isoprenaline (0.1 micrograms/ml); addition of alinidine (3 micrograms/ml), AQ-A 39 (3 micrograms/ml), or propranolol (0.03-0.3 micrograms/ml) reduced sinus rate to the control values. The same concentrations of these drugs were tested in electrically driven (1 Hz) left atria. The positive inotropic effect of isoprenaline was not affected by alinidine and AQ-A 39; however, it was markedly reduced or abolished by propranolol. The experiments, therefore, demonstrated the bradycardic specificity of alinidine and AQ-A 39 under conditions of beta-adrenoceptor stimulation. A cumulative concentration-response curve for the positive chronotropic effect of isoprenaline was established in spontaneously beating atria. AQ-A 39, 1 and 10 micrograms/ml, reduced the control sinus rate but did not affect the following concentration-response curve of isoprenaline. A similar result was published earlier for alinidine and excludes an interaction of both drugs with isoprenaline on a possible subgroup of selective beta-adrenoceptors in the sinoatrial node.
The new bradycardic agent UL-FS 49 (1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-[[2-(3,4-dimethoxyphenyl]ethyl] methylimino]propyl]-2H-3-benzazepin-2-on-hydrochloride) was investigated in isolated guinea pig atria. In spontaneously beating preparations UL-FS 49, (0.03 and 0.1 microgram/ml) reduced the rate of contraction and decreased the maximal effect of isoprenaline added thereafter. The cumulative concentration-response curve of isoprenaline was antagonized, but not in a competitive manner, excluding an interaction at the beta-adrenoceptor. The rate of spontaneous electrical activity in sinoatrial node preparations was increased by superfusion with isoprenaline (0.1 microgram/ml). Addition of UL-FS 49 (0.1 microgram/ml) as well as propranolol (0.3 microgram/ml) reduced rate to control values. In electrically driven (1 Hz) left atria UL-FS 49 (1 microgram/ml) did not reduce contractile force and did not antagonize the positive inotropic effect of isoprenaline added cumulatively thereafter. When contractile force was first elevated by isoprenaline (0.1 microgram/ml), addition of UL-FS 49 (0.1 microgram/ml) did not affect contractility, whereas propranolol (0.3 microgram/ml) abolished the positive inotropic effect of isoprenaline. The experiments, therefore, demonstrate the specificity of UL-FS 49 to decrease heart rate but not contractility during beta-adrenoceptor stimulation. In contrast to propranolol (0.3 microgram/ml) UL-FS 49 (0.1 microgram/ml) also reduced sinoatrial rate elevated by histamine (1 microgram/ml) or theophylline (300 micrograms/ml), thus indicating a possible use as an antitachycardic drug at tachycardias of various origins. In sinus node preparations depolarized by high external K+ concentrations (10.8 mM), the bradycardic effect of UL-FS 49 (0.1 microgram/ml) was diminished.(ABSTRACT TRUNCATED AT 250 WORDS)